Darolutamide

• ALADDIN: evaluation of dAroLutamide Addition to anDrogen Deprivation therapy and radIatioN therapy in newly diagnosed prostate cancer with p… Pending
  2024-517285-41-00 Phase III 1 country ARTIC
• Clinical Application of the Androgen Receptor Inhibitor Darolutamide to Upregulate the Prostate-Specific Membrane Antigen (PSMA) Protein Exp… Pending
  2025-520482-52-03 Phase I/II 1 country Amsterdam UMC Stichting
• AZD5305 vs Placebo in Men with Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents. Recruiting
  2023-504214-30-00 Phase III 11 countries AstraZeneca AB
• Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER): A Two-part Phase 2/3 Trial Recruiting
  2022-501551-90-00 Phase II/III 2 countries Ziekenhuis Aan De Stroom
• TulmiSTAR-02: Phase I/II open-label study of tulmimetostat in combination with darolutamide vs. darolutamide, and tulmimetostat with abirat… Recruiting
  2025-521873-15-00 Phase I/II 5 countries Novartis Pharma AG
• Prostate Androgen Response Investigation using a Stratification BIOmarker - PARIS-BIO Recruiting
  2025-520639-17-00 Phase II 1 country Karolinska University Hospital
• SAKK 08/23: Addition of Darolutamide to first line treatment of mCRPC: a randomized open label phase II trial Recruiting
  2024-512132-29-00 Phase II 1 country Swiss Group for Clinical Cancer Research
• Darolutamide and bipolar androgen therapy for mCRPC patients (DaroBAT) Recruiting
  2025-521051-23-00 Phase II 1 country Universitaet Muenster
• EORTC-2238-GUCG: Improving impact of anti-androgen treatments on patient's daily life and their cancer Recruiting
  2023-506817-23-01 Phase III 9 countries European Organisation For Research And Treatment Of Cancer
• Treatment with darolutamide +/- radiation therapy for patients with a castration resistant cancer and metastases detected by functional imag… Recruiting
  2023-509787-15-00 Phase III 2 countries Unicancer
• DAROTAXEL Recruiting
  2024-516939-28-00 Phase II 1 country Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
• Treatment with darolutamide +/- radiation therapy for patients with a castration resistant cancer and metastases detected by functional imag… Recruiting
  2023-507482-26-00 Phase III 4 countries Unicancer
• Study evaluating whether giving 177Lu-PSMA-617 to men having a spreading prostate cancer which does not respond well to the current standard… Recruiting
  2022-502408-57-00 Phase III 6 countries Unicancer
• A Phase 1/2, Open-Label, Randomized, Dose Finding and Dose Expansion Study of Gedatolisib in Combination with Darolutamide in Metastatic Cas… Recruiting
  2023-505898-32-00 Phase I/II 2 countries Celcuity Inc.
• Evaluation of the impact of metastasis-directed therapy in patients with castration-refractory prostate cancer and a maximum of 5 progressiv… Recruiting
  2022-502254-13-00 Phase III 1 country UZ Leuven
• Randomised phase III trial of ADT +/- darolutamide in frail men with castration-naïve de novo metastatic prostate cancer Recruiting
  2022-502425-18-00 Phase III 10 countries Unicancer
• ProBio: An outcome-adaptive and randomised multi-arm biomarker driven study in patients with metastatic prostate cancer Recruiting
  2023-506857-40-00 Phase III 3 countries Karolinska Institutet
• An international prospective open-label, multi-center, randomized, non-comparative phase II study of lutetium [177Lu] vipivotide tetraxetan … Ended
  2022-503040-41-00 Phase II 7 countries Novartis Pharma AG
• SatisfACtion: A Phase I/II, open-label, multi-center study of [225Ac]Ac-PSMA-R2 in men with metastatic hormone sensitive prostate cancer (mH… Ended
  2023-507672-52-00 Phase I (FiH) 1 country Novartis Pharma AG
• A study to compare the study treatment darolutamide in combination with androgen deprivation therapy (ADT) to placebo in combination with AD… Ended
  2022-501343-33-00 Phase III 14 countries Bayer AG; Bayer Consumer Care AG
• SUrGery with or without dARolutamide in high-risk and/or locally advanced prostate cancer Ended
  2022-501518-67-00 Phase II 1 country Oncopole Claudius Regaud
• A randomised, phase 3 trial comparing 3-weekly docetaxel 75 mg/m2 versus 2-weekly Docetaxel 50 mg/m2 in combination with Darolutamide + ADT … Ended
  2022-502634-52-00 Phase III 2 countries Friedrich-Schiller-Universitaet Jena
• DARIUS : A randomized non-comparative phase II multicentric trial on short term DARolutamide (ODM-201) concomitant to radiation therapy for … Ended
  2023-509494-23-00 Phase II 1 country Institut Bergonie
• Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (PETRANHA) Ended
  2023-508536-64-00 Phase I/II 1 country AstraZeneca AB

Showing 1–24 of 31 trials